NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court

Natco Pharma appoints Bhimrao Dattu Jadhav as Senior VP – Operations (Formulations) for Pharma Division – Kothur

Jadhav has completed his B.Pharmacy and is having 30+ years of rich experience in operation management in pharmaceutical Industry

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.

Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals

Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic

NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage

Natco Pharma announces submission of TABRECTA to USFDA

TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA

Fresenius Kabi USA flies complaint against NATCO Pharma

Natco Pharma intends to defend the matter accordingly

NATCO Pharma receives warning letter from USFDA for facility in Kothur, Telangana

The company will respond to the Warning Letter within the stipulated timelines

Natco Pharma and Breckenridge dismissed from antitrust lawsuit